Richard S Levy Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 15 hours ago
Richard S Levy has an estimated net worth of at least $31.4 million*, as of yesterday. They own 27,697 shares of MDGL stock. They have sold 51,989 shares of MDGL stock since 2021, for an estimated $17.1 million.
Richard S Levy $MDGL SEC Form 4 Insider Trading
Richard S Levy has filed a total of 35 insider trades in $MDGL since 2021. Their most recent trade was a sale of 146 shares, made on Nov 13, 2025. Their largest trade was a sale of 5,227 shares, made on Jan 17, 2023. We estimate that they now own 27,697 shares of $MDGL, worth an estimated $14.3 million.
Insider Trading at $MDGL
There have been a total of 651 insider trades reported at $MDGL since 2021, with 590,368 shares purchased and 877,006 shares sold. The most active insider traders in $MDGL stock have been Brian Joseph Lynch, Mardi Dier, and Rebecca Taub. The most recent trade was a sale of 844 shares reported by David Soergel (Chief Medical Officer), made on May 18, 2026.
History of Insider Stock Trades by Richard S Levy
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
MDGL
|
Sale | 146 | Nov 13, 2025 | Nov. 14, 2025, 6:12 p.m. |
MDGL
|
Sale | 40 | Nov 13, 2025 | Nov. 14, 2025, 6:12 p.m. |
MDGL
|
Sale | 440 | Nov 13, 2025 | Nov. 14, 2025, 6:12 p.m. |
MDGL
|
Sale | 200 | Nov 13, 2025 | Nov. 14, 2025, 6:12 p.m. |
MDGL
|
Sale | 120 | Nov 13, 2025 | Nov. 14, 2025, 6:12 p.m. |
MDGL
|
Sale | 153 | Nov 13, 2025 | Nov. 14, 2025, 6:12 p.m. |
MDGL
|
Sale | 811 | Nov 13, 2025 | Nov. 14, 2025, 6:12 p.m. |
MDGL
|
Sale | 1,434 | Nov 13, 2025 | Nov. 14, 2025, 6:12 p.m. |
MDGL
|
Sale | 1,094 | Nov 13, 2025 | Nov. 14, 2025, 6:12 p.m. |
MDGL
|
Sale | 308 | Nov 13, 2025 | Nov. 14, 2025, 6:12 p.m. |
MDGL
|
Sale | 1,355 | Nov 13, 2025 | Nov. 14, 2025, 6:12 p.m. |
MDGL
|
Sale | 835 | Nov 13, 2025 | Nov. 14, 2025, 6:12 p.m. |
MDGL
|
Sale | 645 | Nov 13, 2025 | Nov. 14, 2025, 6:12 p.m. |
MDGL
|
Sale | 919 | Nov 13, 2025 | Nov. 14, 2025, 6:12 p.m. |
MDGL
|
Sale | 5,000 | Nov 07, 2024 | Nov. 8, 2024, 6:07 p.m. |
MDGL
|
Sale | 800 | Nov 01, 2024 | Nov. 5, 2024, 8:01 p.m. |
MDGL
|
Sale | 1,100 | Nov 01, 2024 | Nov. 5, 2024, 8:01 p.m. |
MDGL
|
Sale | 2,800 | Nov 01, 2024 | Nov. 5, 2024, 8:01 p.m. |
MDGL
|
Sale | 300 | Nov 01, 2024 | Nov. 5, 2024, 8:01 p.m. |
MDGL
|
Sale | 4,387 | Apr 01, 2024 | April 3, 2024, 8:47 p.m. |
MDGL
|
Sale | 3,900 | Apr 01, 2024 | April 3, 2024, 8:47 p.m. |
MDGL
|
Sale | 1,600 | Apr 01, 2024 | April 3, 2024, 8:47 p.m. |
MDGL
|
Sale | 100 | Apr 01, 2024 | April 3, 2024, 8:47 p.m. |
MDGL
|
Sale | 713 | Apr 01, 2024 | April 3, 2024, 8:47 p.m. |
MDGL
|
Sale | 300 | Apr 01, 2024 | April 3, 2024, 8:47 p.m. |
MDGL
|
Sale | 3,548 | Jan 17, 2023 | Jan. 19, 2023, 8:57 p.m. |
MDGL
|
Sale | 5,227 | Jan 17, 2023 | Jan. 19, 2023, 8:57 p.m. |
MDGL
|
Sale | 3,325 | Jan 17, 2023 | Jan. 19, 2023, 8:57 p.m. |
MDGL
|
Sale | 1,600 | Jan 17, 2023 | Jan. 19, 2023, 8:57 p.m. |
MDGL
|
Sale | 300 | Jan 17, 2023 | Jan. 19, 2023, 8:57 p.m. |
MDGL
|
Sale | 100 | Jan 17, 2023 | Jan. 19, 2023, 8:57 p.m. |
MDGL
|
Sale | 400 | Jan 17, 2023 | Jan. 19, 2023, 8:57 p.m. |
MDGL
|
Sale | 500 | Jan 17, 2023 | Jan. 19, 2023, 8:57 p.m. |
MDGL
|
Sale | 2,325 | Jan 17, 2023 | Jan. 19, 2023, 8:57 p.m. |
MDGL
|
Sale | 5,164 | Jan 17, 2023 | Jan. 19, 2023, 8:57 p.m. |
$MDGL Executives and Stock Owners with Insider Trades
-
Brian Joseph Lynch, SVP and General Counsel
-
Mardi Dier, EVP and CFO
-
Rebecca Taub, Pres., R&D, and CMO
-
Carole Huntsman, Chief Commercial Officer
-
Robert E. Waltermire, Senior VP, Chief Pharma Dev.
-
Remy Sukhija, Chief Commercial Officer
-
Shannon T Kelley, General Counsel
-
William John Sibold, President and CEO
-
Mardi Dier, SVP and CFO
-
David Soergel, Chief Medical Officer
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.